Furthermore, a combination of targeted therapeutic regimens for IDH1/2 or FLT3 mutation patients came up with great clinical dealing for secondary AML as it was a one-size-fits-all for all [29]. The gene discussed is FLT3; the disease is acute myeloid leukemia.